StockData

BioAge Labs vs HCW Biologics

BIOA and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIOA and HCWB compare

BioAge Labs is the larger company, worth 163 times as much as HCW Biologics ($240M against $1.5M).

HCW Biologics grew revenue faster over the last twelve months (700% versus 168% for BioAge Labs).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −912% at BioAge Labs.

BioAge Labs scores higher on the StockData Score (8 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIOAHCWB
Size and price
Market cap$240M$1.5M
Share price$5.22$0.800
Change, 1 year−32.4%−94.6%
Change, 5 years–−99.9%
Beta (5Y)2.402.44
Employees62–
StockData Score
Total score8 (better)6
Valuation score13 (better)
Growth score12 (better)
Performance score11
Health score5 (better)0
Dividend score00
Valuation
P/S23.1×0.2× (better)
P/B0.6×0.2× (better)
FCF yield−36.8%–
Fair value–$15.29
Margin of safety–94.8%
Growth
Revenue growth (TTM)168%700% (better)
Revenue growth, 5Y average–−57.9%
Profitability
Gross margin–96.7%
Operating margin−1026%−115% (better)
Net margin−912%−83.8% (better)
FCF margin−851%–
Return on equity−28.2% (better)−151%
Return on invested capital−283%−70.7% (better)
Financial health
Debt / equity0.000.88 (better)
Interest coverage−378.2×−14.0× (better)
Current ratio17.19 (better)0.06
Altman Z-score5.27 (better)−7.20
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.2%5.6%
Held by insiders21.9%34.9%
Insider net buying, 12 months−$7.8M$532K (better)
Short interest, % of float10.4%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.